DynPort Vaccines

DynPort Vaccine Company (DVC) is a U.S.-based government services contractor specializing in the development and licensure of vaccines and therapeutics for biodefense and public health emergencies. Operating as part of GDIT, it provides end-to-end program management, regulatory strategy, clinical research, and manufacturing oversight for complex government-funded medical countermeasure programs. With over two decades of experience, DVC has a proven track record in navigating the FDA regulatory pathway, including submissions under the Animal Rule, and serves as a critical partner for federal agencies in protecting military and civilian populations.

Integrated service platform for biopharmaceutical development, including program management, regulatory strategy (specializing in FDA Animal Rule), clinical trial operations, nonclinical study oversight, process development, and quality/compliance systems for government contracts.

DVC competes with other large government services contractors with life sciences divisions (e.g., Leidos, Battelle, MRIGlobal) and specialized biopharmaceutical development consultancies that bid on government contracts. Its key competitive advantages are its long-term incumbent status on major programs, specialized expertise in the FDA Animal Rule, and the financial/contracting backbone of its parent company, General Dynamics.